Australian Pharmaceutical Industries Ltd

Australian Pharmaceutical Industries Ltd

Consumer ServicesFood & Drug Retailers
  • Price (AUD)1.27
  • Today's Change-0.005 / -0.39%
  • Shares traded1.08m
  • 1 Year change-6.99%
  • Beta1.1203
Data delayed at least 20 minutes, as of May 21 2019 07:10 BST.
More ▼

Profile data is unavailable for this security.

About the company

Australian Pharmaceutical Industries Limited is a pharmaceutical distributor, and health and beauty retailer. The Company operates through two segments: Australia, which is engaged in the distribution of pharmaceutical, medical, health, beauty and lifestyle products to pharmacies, the purchase and sale of various health, beauty and lifestyle products within the retail industry, and the provision of retail services to pharmacies, and New Zealand, which manufactures and owns rights of pharmaceutical medicines and consumer toiletries. Its services include wholesale product delivery, retail services, marketing programs and business advisory services. Its brands include Priceline & Priceline Pharmacy, which is a health, beauty and wellbeing retailer; Soul Pattinson Chemist, which is a pharmacy brand; Pharmacist Advice, which offers professional service and advice; Club Premium, which is a club for independent pharmacies, and Pharmacy Best Buys, which offers a catalog program.

  • Revenue in AUD (TTM)4.00bn
  • Net income in AUD47.36m
  • Incorporated1910
  • Employees5.11k
  • Location
    Australian Pharmaceutical Industries LtdL 5 250 Camberwell RdMELBOURNE 3124AustraliaAUS
  • Phone+61 38855-3000
  • Fax+61 38855-3401
  • Websitehttp://www.api.net.au/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
API:ASX since
Sigma Healthcare LtdAnnounced14 Dec 201814 Dec 2018Announced-13.95%457.15m
Clearskincare Clinics Pty Ltd-Clinic BusinessDeal completed25 Jun 201825 Jun 2018Deal completed-6.99%94.77m
Clearskincare Clinics Pty Ltd-Skincare Products BusinessDeal completed25 Jun 201825 Jun 2018Deal completed-6.99%--
Data delayed at least 20 minutes, as of May 21 2019 07:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Apex Healthcare Berhad226.20m20.30m358.40m1.36k17.642.6715.191.580.49780.49785.553.281.316.544.35480,958.0011.7710.0915.4213.3323.7722.758.997.171.97--0.071832.715.229.3031.7614.3011.1211.03
Shanghai No.1 Pharmacy Co Ltd259.24m7.49m465.76m934.0062.203.40--1.800.16030.16035.552.931.094.549.291,325,422.003.163.724.675.4418.6515.702.892.761.34--0.032932.032.442.77-5.563.60-24.233.71
Genky DrugStores Co Ltd1.34bn43.08m543.47m810.0012.621.626.370.4054211.61211.616,586.491,650.571.705.37140.23125,862,400.005.475.228.519.2523.3622.393.212.900.1906213.530.448210.2413.7511.669.5838.009.900.00
CAWACHI LTD.3.48bn26.51m578.71m2.60k20.270.43956.140.166188.3288.3211,611.804,072.721.456.7779.65--1.100.74091.641.1121.5921.280.76130.50810.6389106.890.250977.05-1.221.77-47.890.0099-17.880.00
Australian Pharmaceutical Industries Ltd4.00bn47.36m625.52m5.11k13.291.24--0.15630.09560.09568.071.032.738.616.54--3.291.506.613.4013.1812.681.210.55770.85699.690.3522133.77-0.78654.97-8.2414.620.473618.20
Yakuodo Co Ltd1.21bn38.73m628.28m653.0016.222.459.740.5204149.19149.194,650.91985.912.405.64239.09--7.717.3112.9312.4023.3623.033.212.980.1742--0.267414.7310.4812.040.925319.9312.8520.30
NIHON CHOUZAI Co.,Ltd.3.23bn49.84m790.26m4.08k15.181.375.190.2446247.07247.0715,782.212,739.061.357.0612.69--2.082.953.364.9317.0917.641.542.130.733213.020.658815.061.838.24-37.9114.80-7.007.39
Qol Holdings Co Ltd1.88bn52.09m803.24m4.68k15.221.597.610.4263103.17103.173,731.65986.701.6118.647.9930,625,480.004.444.917.128.5312.5212.352.772.621.17--0.388524.4910.6613.6414.5429.88-5.697.63
HPGC Renmintongtai Pharmaceutical Corp1.53bn54.84m847.60m2.48k15.462.45--0.55340.45160.451612.612.851.578.572.702,945,830.005.614.2014.4310.0912.6012.633.582.481.2323.690.163954.56-11.9117.301.44109.03-29.53--
Data as of May 21 2019. Currency figures normalised to Australian Pharmaceutical Industries Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

24.97%Per cent of shares held by top holders
HolderShares% Held
Colonial First State Asset Management (Australia) Ltd.as of 21 Mar 201928.06m5.70%
LSV Asset Managementas of 03 May 201924.34m4.94%
Dimensional Fund Advisors LPas of 31 Jan 201916.83m3.42%
Investors Mutual Ltd.as of 30 Apr 201916.69m3.39%
Norges Bank Investment Managementas of 31 Dec 201811.73m2.38%
The Vanguard Group, Inc.as of 30 Apr 201910.07m2.05%
Vanguard Investments Australia Ltd.as of 30 Apr 20194.79m0.97%
Segall Bryant & Hamill LLCas of 31 Mar 20194.17m0.85%
BlackRock Fund Advisorsas of 02 May 20193.99m0.81%
Jackson National Asset Management LLCas of 31 Dec 20182.32m0.47%
More ▼
Data from 31 Dec 2018 - 30 Apr 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.